Failure of scabies treatment: a systematic review and meta-analysis

• Published in: British journal of dermatology (1951) 2024-01, Vol.190 (2), p.163-173
• Main Authors: Mbuagbaw, Lawrence, Sadeghirad, Behnam, Morgan, Rebecca L, Mertz, Dominik, Motaghi, Shahrzad, Ghadimi, Maryam, Babatunde, Ifeoluwa, Zani, Babalwa, Pasumarthi, Tejanth, Derby, McKenzie, Kothapudi, Venkata N, Palmer, Nicole R, Aebischer, Anton, Harder, Thomas, Reichert, Felix
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Child; Hexachlorocyclohexane - therapeutic use; Humans; Ivermectin; Malathion - therapeutic use; Permethrin - therapeutic use; Scabies - drug therapy; Treatment Failure
• ISSN: 0007-0963; 1365-2133; 1365-2133
• DOI: 10.1093/bjd/ljad308

Treatment failure is considered to be an important factor in relation to the increase in scabies incidence over the last decade. However, the regional and temporal differences, in addition to the predictors of therapy failure, are unclear. We aimed to conduct a systematic review of the prevalence of treatment failure in patients with scabies and investigation of associated factors. We searched MEDLINE, EMBASE, CINAHL, Web of Science, Scopus, Global Health and the Cochrane Central Register of Controlled Trials from inception to August 2021 for randomized and quasi-randomized trials, in addition to observational studies that enrolled children or adults diagnosed with confirmed or clinical scabies treated with permethrin, ivermectin, crotamiton, benzyl benzoate, malathion, sulfur or lindane, and measured treatment failure or factors associated with treatment failure. We performed a random effects meta-analysis for all outcomes reported by at least two studies. A total of 147 studies were eligible for inclusion in the systematic review. The overall prevalence of treatment failure was 15.2% [95% confidence interval (CI) 12.9-17.6; I2 = 95.3%, moderate-certainty evidence] with regional differences between World Health Organization regions (P = 0.003) being highest in the Western Pacific region (26.9%, 95% CI 14.5-41.2). Oral ivermectin (11.8%, 95% CI 8.4-15.4), topical ivermectin (9.3%, 95% CI 5.1-14.3) and permethrin (10.8%, 95% CI 7.5-14.5) had relatively lower failure prevalence compared with the overall prevalence. Failure prevalence was lower in patients treated with two doses of oral ivermectin (7.1%, 95% CI 3.1-12.3) compared with those treated with one dose (15.2%, 95% CI 10.8-20.2; P = 0.021). Overall and permethrin treatment failure prevalence in the included studies (1983-2021) increased by 0.27% and 0.58% per year, respectively. Only three studies conducted a multivariable risk factor analysis; no studies assessed resistance. A second dose of ivermectin showed lower failure prevalence than single-dose ivermectin, which should be considered in all guidelines. The increase in treatment failure over time hints at decreasing mite susceptibility for several drugs, but reasons for failure are rarely assessed. Ideally, scabicide susceptibility testing should be implemented in future studies.